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In spite of the strong epidemiologic evidence linking migraine and ischemic stroke in young adults, the mechanisms explaining
this association remain poorly understood. The observation that stroke occurs more frequently during the interictal phase of
migraine prompts to speculation that an indirect relation between the two diseases might exist. In this regard, four major issues
might be considered which may be summarized as follows: (1) the migraine-ischemic stroke relation is inﬂuenced by speciﬁc
risk factors such as patent foramen ovale or endothelial dysfunction and more frequent in particular conditions like spontaneous
cervical artery dissection; (2) migraine is associated with an increased prevalence of cardiovascular risk factors; (3) the link is
caused by migraine-speciﬁc drugs; (4) migraine and ischemic vascular events are linked via a genetic component. In the present
paper, we will review epidemiological studies, discuss potential mechanisms of migraine-induced stroke and comorbid ischemic
stroke, and pose new research questions.
1.Introduction
Migraine aﬀects about 15% of people in developed countries
[1] and is three times more common in women than in
men. Patients have a median of one attack per month, and
25% have at least two attacks per month [2]. Patients with
more than one attack per month are at increased risk of
brain lesions [3]. In the last decades, several studies have
emphasized the high prevalence of migraine among young
individuals with stroke as well as a dysfunction of cerebral
arteries during migraine attacks and the ﬁnding of silent
infarct-like brain lesions in migraineurs, thus leading to
the hypothesis that a comorbidity between migraine and
cerebral ischemia exists [4].
2. Evidence of Association
The ﬁrst epidemiological suggestion that migraine may be
an independent risk factor for stroke came from the Col-
laborative Group for the Study of Stroke in Young Women,
published in 1975, which showed an increased relative risk of
stroke with migraine compared with neighbor controls [5].
Since then, the association of migraine with the risk of stroke
has been investigated in several observational studies, most
of which have been summarized in a recent meta-analysis
[6].
According to this meta-analysis, the pooled relative risk
of ischemic stroke among patients with any type of migraine
is 1.73 (95% CI, 1.31 to 2.29). The relative risk for women
is increased (RR 2.08, 95% CI 1.13 to 3.84) but not for men
(RR 1.37, 95% CI 0.89 to 2.11). Stratifying analysis by age,
people with migraine aged less than 45 have an higher risk
than the overall group (RR 2.65, 95% CI 1.41 to 4.97), which
was further increased among young women (RR 3.95, 95%
CI 2.21 to 6.04).
The risk is apparently more than tripled by smoking (RR
9.09, 95% CI 4.22 to 19.34) and more pronounced by oral
contraceptives (OCs) use (RR 7.02, 95% CI 1.51 to 32.68).
In line with this analysis, data from the Stroke Prevention
in Young Women study (SPYW) showed a higher risk of
stroke in women with probable migraine with visual aura
who were cigarette smokers and oral contraceptive users2 Stroke Research and Treatment
[7]. Overall, these observations reinforced the hypothesis
that speciﬁc subgroups of patients in which the migraine-
stroke pathogenic link is more expressed might be identiﬁed.
Moreover, the meta-analysis found an increased risk of
ischemic stroke among people who had migraine with aura
(MA) (RR 2.16, 95% CI, 1.53 to 3.03) but not among
those who had migraine without aura (MO) (RR 1.23,
95% CI 0.90 to 1.69), challenging whether MO should be
considered a stroke risk factor. Is this enough to conclude
that migraine is a risk factor for stroke? Some limitations
of the included studies should be considered. First, migraine
is biologically heterogeneous [8], and latent class analysis of
migraine symptoms indicated the existence of a continuum
of severity, with MA being more severe but not etiologically
distinct from MO, thus reinforcing the view that the two
migraine subtypes are not separate entities [9, 10]. The
use of the categories of the International Headache Society
classiﬁcation [11] as phenotypes (MO and MA) might
present an oversimpliﬁed picture of migraine phenotype,
which in reality has a complex genetic and environmental
background, and using this phenotype might result in too
heterogeneous a set of patients for association analyses.
As in other complex diseases, the use of single traits or
other new phenotyping strategies for migraine might help
in stratifying study samples into less heterogeneous groups.
Second, potential bias in the selection of patients should
be taken into account. At least theoretically, a referral bias
may exist if stroke patients with migraine would be referred
to the recruiting centres more frequently than stroke cases
without migraine, or if the investigators were more prone to
include stroke cases with migraine than without migraine.
A further selection bias could be the consequence of a
stroke-migrainemisdiagnosis.AsTIAaresometimesdiﬃcult
to distinguish from an attack of MA, especially when the
aura occurs without headache, and migraine with prolonged
neurological aura (lasting longer than 24 hours) may mimic
stroke, the end results of such misclassiﬁcations would be an
overestimation of the prevalence of migraine in cases and,
therefore, an overestimation of the risk. Third, in most of
the considered studies, a consistent deﬁnitions for migraine
is lacking. Accurate diagnosis of migraine is important to
avoid nondiﬀerential misclassiﬁcation of exposure, which
will bias the risk estimate towards showing no association.
If this is the case, however, we cannot but assume that
the increased risk of stroke emerging from the pooled
analysis of data from observational studies is rather an
underestimation of the eﬀect. As such, it should be retained
asanargumentin favourof thereported association between
migraine and stroke. Furthermore, in case-control studies,
an interviewer bias and a recall bias can arise as possible
consequences of the retrospective design. Fourth, in some of
the studies, the inﬂuence of several confounders on the ﬁnal
results was not considered, while others were not controlled
for. These include, for example, the use of medications
with a potential eﬀect on stroke risk (i.e., antihypertensive
agents), or risk factors for both migraine and stroke, such
as antiphospholipids antibodies. Finally, most studies are
limited to younger individuals (aged 45 years or younger)
leaving the association between migraine and stroke among
the elderly unclear and ignoring the fact that migraine may
start later in life.
Overall, there is strong epidemiological evidence that
migraine, particularly MA, is associated with increased risk
of cerebral ischemic events, which appears to be stronger
among the young but may persist in the elderly. In this
regard, data from 39,876 US female health professionals
aged 45 or older included in the Women’s Health study
after a mean of 9 years of followup showed that MA
increased 1.5-fold the risk of total stroke after adjusting
for potential confounders of age, hypertension, menopausal
status, contraceptive use, and alcohol consumption (HR
1.53; 95% CI 1.02 to 2.31) and a 1.7-fold the risk of ischemic
stroke (HR 1.71; 95% CI 1.11 to 2.66) when compared to
participants without migraine [12]. In contrast, there was
no association between MO and total stroke or ischemic
stroke. This association between MA and cerebrovascular
disease as well as with ischemic stroke was conﬁrmed in
a large cohort of individuals ≥55 years of age at the time
of migraine assessment, who participated to the Atheroscle-
rosis Risk in Communities (ARICs) study [13]. A recent
population-based cohort study during up to four decades
of followup found that at midlife people with MA were
at increased risk of all-cause mortality (HR 1.21, 95% CI
1.12 to 1.30) and mortality from cardiovascular disease (HR
1.27, 95% CI 1.13 to 1.43) compared with people with no
headache, while those with MO and nonmigraine headache
were not. In particular, people with MA were at increased
risk of mortality from coronary heart disease (HR 1.28,
95% CI 1.11 to 1.49) and stroke (HR 1.40, 95% CI 1.10
to 1.78) [14]. Thus, these ﬁndings provide arguments to
the assumption that migraine may have some inﬂuence
on stroke risk even in older subgroups. However, eﬀect
modiﬁcation by age is evident from prospective data, the
risk of stroke being higher in younger age groups and
decreasing over time, with no increased risk among the
elderly (age 60 or older) according to case-control analyses
[15].
3.What Is the Pathogenic Mechanism Linking
MigraineandStroke?
Although the relationship between migraine and stroke
remains one of the most perplexing problems for neu-
rologists, there are also valid arguments to assume that
the hypothesis of a pathogenic relation between these two
entities is biologically plausible. The observation that stroke
may occur during migraine attacks prompts to speculation
that migraine may directly cause an ischemic event (i.e.,
migrainous infarct). Alternatively, as stroke occurs more
frequentlyduring the interictal phase of migraine, an indirect
relation between the two diseases might exist. In this regard,
four major issues might be considered which may be sum-
marized as follows: (1) migraine-ischemic stroke pathway
is modulated by the intervention of common risk factors;
(2) migraine is associated with an increased prevalence of
cardiovascularriskfactors;(3)thelinkiscausedbymigraine-
speciﬁc drugs; (4) migraine and ischemic vascular events are
linked via a genetic component [16].Stroke Research and Treatment 3
4.IsMigraineaDirect Causeof
Cerebral Ischemia?
“Migrainous infarction” is deﬁned as a stroke occurring
during a typical attack of MA in the IHS migraine clas-
siﬁcation. This condition suggests a causal relationship
between stroke and migraine. Diagnostic criteria include
a history of MA and the neurological deﬁcits occurring
in the same vascular distribution as the aura, persisting
for more than 60 minutes, and being associated with an
ischemic brain lesion in a suitable territory demonstrated
by neuroimaging. Other possible causes of ischemic stroke
have to be excluded by appropriate investigations [11].
However, which investigations should be done and when is
not clear. The absence of causes other than migraine does
not necessarily imply that migraine is the cause, given that
about half of the ischemic strokes in young adults have no
detectable cause. According to large series, the incidence of
migrainous infarction [17–21] varies between 0.5 and 1.5%
of all ischemic strokes and 10 and 14% of ischemic strokes
in young patients. The clinical features typifying migrainous
stroke included female sex, mean age in the low-to-mid-30s,
a history of cigarette smoking, and ischemic involvement of
the PCA territory [19]. Although the limitations inherent in
the diagnostic criteria which might be too strict for a correct
diagnosis of migrainous infarction, and in the consequent
weakness of the epidemiological studies, it seems reasonable
to assume that migrainous infarction does not account for
all strokes occurring during migraine attacks, and, overall,
it is responsible for only a minority of migraine-related
infarcts. Notwithstanding, it represents a useful model
to understand the potential mechanisms underlying the
relationbetweenmigraineandstroke.Migraineisconsidered
to be a neurovascular disorder, in which arterial constriction
and decreased blood ﬂow to the posterior circulation are
consequences of a spreading wave of neuronal depression in
thecerebralcortex(corticalspreading depression,CSD).The
ﬁrst vascular phenomenon associated to CSD is a short-lived
increases in cerebral blood ﬂow (CBF) and tissue hyperoxia
[22] followed by a more profound oligemia and consequent
increased intraparenchymal vascular resistance [23]. Thus,
low ﬂow in major intracerebral vessels may be due to
increased downstream resistance, not major intracranial
arterial vasospasm. Essentially, a prolonged decreased in
CBF and neuronally mediated vasodilatation could cause
sluggish ﬂow in large intracerebral vessels during the aura
of migraine. The combined eﬀect of conditions predisposing
to coagulopathy, such as dehydration hyperviscosity or
intravascular thrombosis, could induce migraine-induced
cerebral infarction, although rarely. Neurogenically medi-
ated inﬂammatory responses accompanying vasodilation
of extra-parenchymal vessels caused by release of vasoac-
tive peptides, nitric oxide (NO), activation of cytokines,
and upregulation of adhesion molecules also predispose
to intravascular thrombosis [24]. This could explain why
migraine-induced stroke usually respects intracranial arte-
rial territories while aura involves more widespread brain
regions. In addition, frequent aura, if due to CSD, could
induce cytotoxic cell damage and gliosis based on glutamate
release or excess intracellular calcium accumulation [25].
Thus, a persistent neurological deﬁcit could be due to
selective neuronal necrosis. Finally, the occurrence of arterial
vasospasm, as a consequence of the release of vasocon-
strictive substances such as endothelin and serotonin, once
thought to be the mechanism of migraine aura, has been




5.1. Potential Common Biologic Mechanisms
5.1.1. Patent Foramen Ovale. Several investigators have
reported an increased prevalence of patent foramen ovale
(PFO), an interatrial septal cardiac abnormality associated
with increased risk of ischemic stroke in young adults in
patients who suﬀered MA than in patients without migraine
[26, 27]. Similarly, in patients with ischemic stroke, MA is
twiceasprevalentinpatientswithPFOthaninthosewithout
[28, 29]. Multiple observational studies, from both single
and multicentre experiences, suggest PFO closure to reduce
the frequency of migraine attacks. In particular, among
migraineurs, this might be proposed for those patients in
the MA subgroup and might indirectly reduce the risk
of stroke, in spite of the small stroke predisposing eﬀect
of PFO and some recent ﬁndings indicating no stronger
association between MA and ischemic stroke among women
with PFO compared with women without [7]. However, the
following limitations in these reports need to be considered
including absence of control group, retrospective design
which implicates recall bias, placebo eﬀect that can result
in up to 70% reduction of attacks frequencies [30, 31],
administration of aspirin after PFO closure, and its potential
prophylactic eﬀect [32]. Paradoxical embolism is suggested
to be the causal link between migraine and PFO, but
insuﬃcient data are available to substantiate the hypothesis
that migraine frequency (and, indirectly, ischemic stroke
risk) is reduced by PFO closure. The only way to address this
issue is by randomization. At present, only one prospective,
randomised, double-blind trial on the therapeutic eﬀect of
PFO device closure on MA patients compared to sham
has been conducted (Migraine Intervention with STARFlex
Technology, MIST) without reaching a positive end point
and being associated with substantial controversy [33, 34]. A
more comprehensive analysis of current data is desirable to
provide information about how to identify patients who may
have an improvement of their migraine, and a large number
of patients with longer followup seems necessary. Other
studies examining the eﬃcacy of PFO closure for prevention
of migraine are under way. Based on all these ﬁndings,
the possibility of a PFO-migraine-ischemic stroke triangular
association remains actually a matter of speculation.
5.1.2.EndothelialDysfunction. Anothertopicofrecentatten-
tion is that migraine may be a risk factor for endothelial dys-
function, representing a challenging link to ischemic stroke
and heart disease. Endothelial dysfunction is characterized4 Stroke Research and Treatment
by reduction in bioavailability of vasodilator (such as NO),
increase in endothelial-derived contracting factors, and con-
sequentimpairmentofthereactivityofthemicrovasculature.
It also comprises endothelial activation, characterized by
a procoagulant, proinﬂammatory, and proliferative milieu,
which, in turns, predisposes to an increased rate of cerebro-
and cardiovascular ischemic events. Traditional vascular risk
factors are known to have an unfavorable eﬀect on endothe-
lial function. Therefore, given its biological properties,
vascular endothelium (and, thus, endothelial dysfunction)
can be considered as the “missing link” between any risk
factor and its detrimental vascular eﬀect. In this context,
endothelial dysfunction can be regarded as “the ultimate risk
of the risk factors” [35]. Endothelial dysfunction is mediated
by increased oxidative stress, an important promotor of the
inﬂammatory process [35], which has been proposed in the
pathogenesis of migraine. In fact, compared to migraine-
free controls, oxidative stress markers have been found to
be higher in migraineurs, even during the interictal period,
thus yielding support to the association. These ﬁndings, as
well as the known eﬃcacy of anti-inﬂammatory agents in
migraine attacks, indirectly support this assumption and
further strengthen the hypothesis of a pathogenic relation
migraine-endothelial dysfunction-cerebral ischemia.
5.1.3. Cervical Artery Dissection. In the last years, migraine
has been suggested to be a predisposing condition for
spontaneous cervical artery dissections (sCADs), one of
the most common causes of stroke in young patients
leading to speculation that migraine might be a predisposing
condition for speciﬁc pathogenic subtypes of ischemic stroke
particularly in young patients. In two French case-control
studies, migraine resulted twice as common in patients with
sCAD than in patients whose ischemic stroke was not related
to an sCAD [36, 37], and this association was stronger
and more signiﬁcant in patients with dissections involving
multiple vessels. A large Italian case-control study conﬁrmed
these ﬁndings [38]. The association between sCAD and a
speciﬁc migraine subtype is controversial since it has been
suggested to be stronger for MO than for MA, but recently a
hospital-based case-control study found a higher prevalence
of migraine with aura among sCAD patients as compared to
a control group [39].
The mechanism by which migraine may aﬀect the risk of
sCAD is unknown. A common generalized vascular disorder
is hypothesized to be a predisposing condition for both dis-
eases.Increasedactivityofserumelastase,ametallopeptidase
which degrades speciﬁc elastin-type aminoacid sequences,
reported in migraineurs suggests a possible extracellular
matrix degradation [40] which might facilitate sCAD occur-
rence. Furthermore, in line with previous observations of
altered common carotid artery distensibility in patients with
sCAD [41], Lucas and coworkers recently reported that
the endothelium-dependent vasodilatation assessed in the
brachialarteryissigniﬁcantlyimpairedinthesesubjects[42].
Similar vascular changes have been observed in migraine
patients during interictal periods [43] and replicated in a
recent cross-sectional study in migraineurs of recent onset,
thus excluding possibility of bias due to longstanding history
of migraine and repeated exposure to vasoconstrictor drugs
[44]. Finally, the analysis of small families has shown
that the structural abnormalities related to sCAD might
be familial and follow an autosomal dominant pattern
of inheritance [45, 46]. This implicates that genetically
determined alterations of the extracellular matrix may play
a crucial pathogenic role and that candidate genes involved
in the regulation of the endothelial and the vessel wall
functions, might increase susceptibility to both conditions
[47–49].
6.MigraineandCardiovascularRiskFactors
Several reports have associated migraine with a more
unfavourable cardiovascular risk proﬁle. According to the
results of the Genetic Epidemiology of Migraine (GEM)
study, migraineurs are more likely to smoke and to have
a parental history of myocardial infarction. MA was also
found to be associated with an unfavourable cholesterol
proﬁle, elevated blood pressure, early onset coronary heart
disease, or stroke [50]. Data from the population-based
American Migraine Prevalence and Prevention (AMPP)
study recently provided further support to the perception
that migraineurs have a higher probability of having an
unfavorable risk factors proﬁle [51]. However, a number of
large-scale epidemiologic analyses conducted over the last
years have questioned these ﬁndings and suggested that the
migraine-stroke association is particularly present in the
absence of traditional cardiovascular risk factors [16, 52].
Therefore, the possibility that the relation between migraine
and ischemic stroke may be due to the known pathogenic
eﬀect of traditional vascular risk factors seems unlikely.
7.Effects ofMigraine-SpeciﬁcDrugs
Since the potential of triptans and ergotamine for adverse
vascular eﬀects, in the last years large-scaled studies have
investigated the risk of ischemic events and death in
migraineurs patients treated with these agents. Data from
General Practice Research Database in the United Kingdom
showed that in general practice triptan treatment did not
increase the risk of ischemic events [53]. Similarly, this
ﬁnding was conﬁrmed by a wide retrospective cohort study
from a health care provider in USA [54]. This study
also investigated the rates of vascular events in relation
to ergotamine use ﬁnding no association. Recently, a ret-
rospective nested case-control study using data from the
PHARMO Record Linkage System conducted in Netherlands
investigated whether overuse of triptans and ergotamina is
associated with an increased risk of ischemic events [55].
Results showed that while ergotamine overuse increases
signiﬁcantly the risk of ischemic complications (OR 2.55;
95% CI, 1.22–5.36) especially in patients concomitantly
using cardiovascular drugs (OR 8.52; 95% CI, 2.57–28.2),
overuse of triptan, neither in the general populations nor in
those using cardiovascular drugs increases the risk of cere-
bral, cardiovascular, or peripheral ischemic events. However,
therapeutic doses of either triptans or ergotamines were not
associated with an increased risk of ischemic vascular events.Stroke Research and Treatment 5
Taken together, these ﬁndings suggest that triptan use and
even triptan overuse are generally safe although heighten the
risk of ischemic complications due to ergotamine overuse,
likely in relation to its greater vasoconstrictive properties.
8.GeneticInﬂuence
Based on twin and family history studies, genetic predisposi-
tionhasbeensuggestedtoplayamajorroleintheoccurrence
of both migraine and ischemic stroke. Interestingly, several
candidate genes for migraine are also good candidate for
cerebral ischemia. Among them, in spite of the inconsistent
in migraine [56], the C677T polymorphism of the MTHFR
gene seems particularly promising, because of its probable
independent eﬀect on ischemic stroke risk [57]. In this
regard, recently the results of a genotype-migraine-stroke
interaction study have been reported in which the TT-
genotype of the C677T MTHFR polymorphism was found
to be associated to both diseases and inﬂuence their relation
[58]. Applying a mediation modelling strategy on a group
of patients with sCAD, a group of young patients whose
ischemic stroke was unrelated to an sCAD (non-CAD) and
a group of control subjects, both migraine and the TT-
genotype were found signiﬁcantly associated to the group
of patients with ischemic stroke as compared to controls,
withastrongerstrokesubtypespeciﬁceﬀectforsCAD.These
ﬁndings suggest that migraine may act as mediator in the
MTHFR-ischemic stroke pathway with a more prominent
eﬀect in the subgroup of patients with sCAD and prompt
speculating that the C677T MTHFR polymorphism may be
one of the hitherto unknown factors linking migraine to
cerebral ischemia. These ﬁndings have been replicated in a
separate analysis of the Women’s Health study data [59].
Overall, these ﬁndings may be viewed considering the pre-
vailing hypothesis that migraine and ischemic stroke are the
end phenotype of polygenic disorders reﬂecting the eﬀect of
several genetic loci modulating diﬀerent pathophysiological
processes and the combination of many hundreds of genetic
variants; as a consequence, it is reasonable to hypothesize
that certain genes might have an eﬀect on both diseases
and inﬂuence their relation. At what levels in the migraine-
stroke pathway these genetic inﬂuences might be operating
to increase the propensity to cerebral ischemia and whether
sucheﬀectsmightvaryaccordingtodiﬀerentstrokesubtypes
are important and still poorly investigated aspects of stroke
pathogenesis.
Ischemic stroke and migraine further coexist in the con-
text of some syndrome characterized by peculiar phenotype,
proven inherited background, and chronic alterations of the
wall of cerebral small vessel arteries suggesting a common
pathogenic mechanism shared by these two conditions.
CADASIL is an autosomal dominant disease of vascular
and smooth muscle cells due to Notch-3 mutations [60],
characterized by leucoencephalopathy, small deep infarcts,
and subcortical dementia. MA is usually the ﬁrst manifes-
tation, presenting about 15 years before stroke and before
the appearance of MRI signal abnormalities. MA is present
in one-third of symptomatic subjects, and its frequency can
varygreatlyamongtheaﬀectedpedigrees.In40%offamilies,
more than 60% of symptomatic subjects had a history of
MA [61, 62] and within some families, MA is the most
important clinical aspect of the phenotype. The mechanism
underlying MA in CADASIL is not clear. Presenting 10–
20 years before ischemic manifestations, MA is not the
consequence of subcortical infarcts. In CADASIL, absence
of diﬀerence in the frequency and distribution of white-
matter abnormalities between patients with and without
MA suggests that chronic subcortical hypoperfusion is also
unlikely. Another hypothesis is that MA directly relates
to dysfunction of smooth muscle cells of meningeal and
cortical vessels, triggering CSD [63]. Furthermore, if the
cells signalling abnormalities (resulting from the mutation)
extend and reach neurons, the resulting hyperexcitable
membrane instability could predispose to CSD.
Cerebroretinal vasculopathy (CRV) and hereditary
endotheliopathy with retinopathy, nephropathy, and stroke
(HERNS) are two rare inherited conditions characterized by
a primary microangiopathy of the brain in combination with
vascular retinopathy.
Mitochondrial myopathy, encephalopathy, lactic acido-
sis, and stroke-like episodes (MELAS) is associated to
several mutations in mitochondrial DNA (mtDNA). The
phenotypic expression is highly variable ranging from
asymptomatic state to severe childhood multisystem disease
with lactic acidosis. Recurrent episodes of headache (mostly
migraine) are part of the clinical spectrum.
Migraine is also part of the clinical spectrum of
hereditary haemorragic teleangiectasia (HHT; Osler-Weber-
Rendu disease), an autosomal dominant vascular dysplasia
characterizedbyahighprevalenceofvascularmalformations
in various organs, including lung, liver, kidney, and brain, as
well as by mucocutaneous teleangiectasias [64].
9. Conclusion
Given all the epidemiological evidence suggesting that
migraine, in particular MA, increases the risk of cerebral
ischemic events, some questions related to the pathogenic
link between migraine and ischemic stroke still remain.
Strong arguments support the assumption that MA is asso-
ciated with a systemic vascular disorder, especially in young
stroke patients. The use of new phenotyping strategies for
migraine and ischemic stroke should be taken into account
in order to provide a more direct insight into the underlying
biology of the two diseases and how to identify migraineurs
at highest risk of ischemic stroke. Whether stroke can be
prevented by migraine prophylaxis, endothelial repair, anti-
inﬂammatory treatment, platelet inhibition, or a combina-
tion of these strategies is a further goal of future research.
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